You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Lactoferrin as an Adjuvant for Cellular Immunity

    SBC: Pharmareview Corporation            Topic: N/A

    The Specific Aims of the proposal will be modified to reflect a change in scope, according to recommendations from the review panel. Specifically, the revised scope of the project will now only include AIM I and AIM II of the proposal. There will be no change in scope to the first two aims. All experiments proposed in AIMs I and II can be accelerated to meet the two year time commitment. Regarding ...

    STTR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  2. CG-GRID: Computational Genetics Grid Resource for Interaction Discovery

    SBC: PARABON COMPUTATION, INC.            Topic: 400

    DESCRIPTION provided by applicant Advances in DNA sequencing technology have now made it practical and affordable to generate datasets containing millions of genetic attributes that can be tested for association with disease susceptibility The computational complexity of searching for genetic interactions over such high dimensional datasets imposes great challenges for genome wide associatio ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Targeting glioblastoma stem-like cells with custom-designed viral vectors

    SBC: Lacerta Therapeutics, Inc.            Topic: 102

    Glioblastoma (GBM) is the most lethal form of adult brain cancers with a median survival of andlt;15 months despite aggressive standard chemoradiation. GBM are formed by GBM stem-like cells (GSCs) - a major contributor to tumor recurrence and a natural focus for therapeutic development. There are two main reasons responsible for treatment failure: 1) high intra- and inter-tumor cellular and molecu ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Preclinical Development of OCF001 for Treatment of Yeast Infections

    SBC: Sano Chemicals, Inc.            Topic: NIAID

    Project Summary Occidiofungins (A-D) are cyclic nonribosomally synthesized antifungal peptides with submicromolar fungicidal activity against a broad spectrum of fungi. Optimization of the production and isolation of occidiofungins from liquid cultures has been performed. The production and isolation of predominantly one analog, called occidiofungin B (OCF001), supports its commercial development ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Microfluidic CAR-T Cell Processing Device

    SBC: GPB Scientific, Inc.            Topic: 101

    ABSTRACT The goal of this Fast-Track STTR project is to develop a Deterministic Lateral Displacement (DLD) microfluidic device that can enrich white blood cells (WBCs) from a typical leukapheresis unit in 1 hr, for use in manufacturing cancer cellular immunotherapy. Chimeric antigen receptor T cell (CAR-T) therapy has been recommended for FDA approval to treat relapsed or refractory pediatric and ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a transgenic rat to study brain aging

    SBC: INFLAME THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Neuro-inflammation is thought to be an important factor in age-dependent loss of neuron associated with Alzheimer's disease. We seek STTR funding to develop a unique transgenic rat that serves as a model for chronic neuro-inflammation and age-dependent loss of neurons. Presently, no other animal model offers specific patterns of neuro-inflammation, presence of ...

    STTR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  7. Clinical validation and commercialization of a novel hydrogel-based vaginal packing system for pelvic brachytherapy

    SBC: BrachyFoam, LLC            Topic: 102

    This proposal aims to complete preclinical validation and commercialize a novel vaginal packing product based upon a biocompatible polymer hydrogel strategy. The hydrogel will form in situ after being injected into a bag placed within the vaginal cavity during pelvic brachytherapy. The hydrogel packing can then be removed readily after the brachytherapy treatment. This Phase II proposal focuses on ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Cyber Forensic Tool Kit for Machinery Control

    SBC: Mission Secure, Inc.            Topic: N16AT013

    The objective of this effort matures a technology called EagleEye Sentinel Hosted – Secure Overlay System Protect (ESH-SOSP), to provide a new security layer for normal cyber physical system (CPS) operations as the basis for detecting system anomalies and cyber-attacks for the U.S. Air Force. ESH-SOSP technology provides the security analyst the means to have all the necessary and relevant ...

    STTR Phase II 2019 Department of DefenseAir Force
  9. Automated Intestinal Electrical Stimulation for Diabetes

    SBC: Transtimulation Research Inc.            Topic: 200

    Diabetes affects more than 9% of Americans and costs over $300 billion in 2017 in USA. Medical therapies have limitations in treating diabetic patients with obesity due their common side effects of weight gain. Bariatric surgery has been proposed for treating diabetic patients with promising outcomes. In this project, we propose a novel method of intestinal electrical stimulation (IES) for treatin ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Next Generation Tools for Onsite Monitoring and Treatment of Drug of Abuse-Dependent Persons

    SBC: SensoDX II, LLC            Topic: NIDA

    Abstract Opioid abuse disorder (OAD) affects 2.1 million of Americans annually resulting in overdoses numbering in the tens of thousands and skyrocketing rates of mortality. In addition to its enormous social impact, OAD carries a multi-billion-dollar price tag that includes $78.5 billion, specifically for health care and other costs related to prescription opioid abuse and misuse. Although effect ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government